Transgene Biotek Ltd. (BSE: 526139) is a Sangareddy, Telangana-based company in the Biological Products industry. With a market capitalisation of ₹19 Cr, it ranks #4,654 by market cap among the 6,189 Indian listed companies on FinBizNet, and #4 of 5 in Biological Products. At ₹2.57 (as of 26 Oct 2026), the share price is 40.4% below its 52-week high of ₹4.31 and 40.4% above its 52-week low of ₹1.83. The share price is down 39.2% over one year and down 15.5% over three months.
| Current Price | ₹2.57 |
|---|---|
| Market Cap | ₹19 Cr |
| BSE Code | 526139 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Biological Products |
| P/E Ratio | -11.7 |
| Return on Equity | -17.96% |
| Return on Assets | -0.32% |
| 52-Week Range | ₹1.83 – ₹4.31 |
| 1-Year Price Change | -39.2% |
| 3-Month Price Change | -15.5% |
| Beta (1Y) | 0.88 |
| Headquarters | Sangareddy, Telangana |
| Website | www.transgenebiotek.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹-0 Cr |
| Net Margin | -650.0% |
| EPS (Basic) | ₹0.05 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
1. Bulk Drugs-This segment engages in the research and development of hepatitis B vaccines in India. It offers oncology drugs, oral drug delivery, and biogenerics. It offers TrabiDHA for use in health foods, baby food/formulas, health supplements, and chicken and animal feed; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. 2. Diagnostic Services-This segment provides diagnostic services. 3. CRO Services-This segment provides clinical research organization services. 4. Unallocated Other Income-0
1. Bulk Drugs-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Biocon Limited | ₹52,675 Cr | 114.7 | 1.15% | ₹4,336 Cr | -9.7% |
| Hester Biosciences Ltd | ₹1,744 Cr | 31.4 | 16.55% | ₹77 Cr | +19.5% |
| Zenotech Laboratories Ltd | ₹246 Cr | -223.9 | -1.12% | — | -20.3% |
| Transgene Biotek Ltd. | ₹19 Cr | -11.7 | -17.96% | ₹0 Cr | -39.2% |
| Hindustan Bio Sciences Ltd | ₹7 Cr | -86.3 | -9.12% | — | -18.7% |
Listed by market capitalisation. Ratios are shown for context only.
Transgene Biotek Ltd. is trading at ₹2.57, with a market capitalisation of ₹19 Cr.
Transgene Biotek Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Biological Products).
Transgene Biotek Ltd. has a P/E of -11.7 and a return on equity of -17.96%.
Transgene Biotek Ltd. is listed on the BSE under the scrip code 526139.
Transgene Biotek Ltd.'s share price is down 39.2% over one year and down 15.5% over three months. Its 52-week range is ₹1.83 to ₹4.31.
In Q1 FY27, Transgene Biotek Ltd. reported revenue of ₹0 Cr and net profit of ₹-0 Cr, with basic EPS of ₹0.05 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.